5-(苄基硫代)-N-甲基-1,3,4-噻二唑-2-胺
5-(苄基硫代)-N-甲基-1,3,4-噻二唑-2-胺
5-(苄基硫代)-N-甲基-1,3,4-噻二唑-2-胺 性质
| 沸点 | 389.6±35.0 °C(Predicted) |
|---|---|
| 密度 | 1.31±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 二甲基亚砜：125 mg/mL（526.67 mM） |
| 酸度系数(pKa) | 2.67±0.10(Predicted) |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
| InChI | 1S/C10H11N3S2/c1-11-9-12-13-10(15-9)14-7-8-5-3-2-4-6-8/h2-6H,7H2,1H3,(H,11,12) |
| InChIKey | KFLNRVSOQJTXDG-UHFFFAOYSA-N |
| SMILES | [s]1c(nnc1NC)SCc2ccccc2 |
5-(苄基硫代)-N-甲基-1,3,4-噻二唑-2-胺 用途与合成方法
IC50: 220 nM (GPR171).
MS21570 significantly attenuates this CNO-mediated increase in food intake. Interestingly, MS21570 causes a significant increase in center time compared to vehicle suggesting an effect on the anxiety-like behavior. Intra-BLA administration of MS21570 leads to an increase in open arm time on the elevated plus maze although there is no effect on locomotor activity during this test. Interestingly, when administered before and immediately following fear conditioning, MS21570 significantly attenuates freezing measured 24 hours later. Behavioral differences between systemic and intra-BLA administration of MS21570 could be due to the pharmacokinetic and pharmacodynamic properties of the drug. Further studies are needed to characterize the GPR171 antagonist.
5-(苄基硫代)-N-甲基-1,3,4-噻二唑-2-胺 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-112620 | 5-(苄基硫代)-N-甲基-1,3,4-噻二唑-2-胺 | 65373-29-7 | 5 mg | 562 |
| 2026-09-15 | HY-112620 | 5-(苄基硫代)-N-甲基-1,3,4-噻二唑-2-胺 | 65373-29-7 | 10mM * 1mLin DMSO | 618 |
